A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma
Conclusions Although 2 patients had stable disease at 6 months, the short median time to progression and lack of any objective responses indicate that single agent cediranib at this dose and schedule is not sufficiently active to warrant study continuation.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anorexia | Cancer & Oncology | Drugs & Pharmacology | Eating Disorders & Weight Management | Hematology | Hypertension | Investigational New Drugs | Melanoma | Skin Cancer | Study | Toxicology